Updates are available New edition dated 2018-10-01

Click to view New edition: https://doi.org/10.17352/ojcps.000001

Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions

Crossref DOI link: https://doi.org/10.17352/ojcps.000001

Published Online: 2018-10-01

Update policy: https://doi.org/10.17352/crossmark-policy

About CrossMark